紫鑫藥業(002118.SZ):股東仲維光所持6192.26萬股司法拍賣股份流拍
格隆匯 11 月 11日丨紫鑫藥業(002118.SZ)公佈,公司於2020年10月13日披露了《關於股東股份被司法拍賣的提示性公告》,公司控股股東敦化市康平投資有限責任公司的一致行動人仲維光持有公司的無限售流通股份:約6192.26萬股(佔公司股份總數的4.83%,佔其持有公司股份總數的100%)於2020年11月10日10時至2020年11月11日10時止(延時除外)在“淘寶網”(sf.taobao.com)上進行公開拍賣活動,拍賣輔助機構為上海拍賣行有限責任公司。根據拍賣網絡平台頁面顯示的拍賣結果,此次拍賣流拍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.